AMGN Amgen

  • STOCK
  • AMGN
  • Price as of: Dec 19, 10:23 PM EST
  • $170.17
  • +$1.69
  • +1.0%
  • Industry
  • Biotechnology
Share

AMGN Stock Dividend Data

Add AMGN to Watchlist
  • Dividend Yield
    1.86% Healthcare Average 2.29%
  • Annual Payout
    $3.16 Paid Quarterly
  • Payout Ratio
    36.8% EPS $8.59
  • Dividend Growth
    3 yrs Since 2011
  • Get AMGN DARS™ Rating
DARS Rating™ Breakdown

Dividend.com DARS Rating™ Breakdown for AMGN

Sign Up
Metric AMGN Rank AMGN Avg Ranking Notes
Relative Strength Sign Up For Ticker Ranking Sign Up For Sector Ranking Stock is at the top of its six-month trading range.
Overall Yield Attractiveness Sign Up For Ticker Ranking Sign Up For Sector Ranking Stock's dividend yield is adequate.
Dividend Reliability Sign Up For Ticker Ranking Sign Up For Sector Ranking This rating is related to the length and consistency of a company's dividend payouts, as well as our opinion on how likely the company is to continue payouts in the future.
Dividend Uptrend Sign Up For Ticker Ranking Sign Up For Sector Ranking Dividend payouts are consistent, but increases small.
Earnings Growth Sign Up For Ticker Ranking Sign Up For Sector Ranking Earnings estimates are uptrending.
DARS Rating Sign Up For Ticker Ranking Sign Up For Sector Ranking Sign Up For DARS Ratings
Growth History

AMGN Dividend Growth History

Annualized Growth
1994-2012
Annualized Growth
1994-2004
Annualized Growth
2004-2008
Annualized Growth
2008-2012
Annualized Growth
Last 5 Yrs
Annualized Growth
Last 3 Yrs
Annual
Growth
2012
Consecutive
Years of
Increases
Reveal More Dividend Growth History for AMGN NA% 30.6% 3 years
Reveal More Dividend Growth History for AMGN
Historical Annual Dividend Data & Growth

AMGN Historical Annual Dividend Data & Growth

Payout Amount Calendar Year Annual Growth
$1.8800 2013 30.6%
Historical Dividend Data

AMGN Dividend History

Payout Amount Declared Date Ex-Dividend Date Record Date Pay Date ▼ Qualified Dividend? Payout Type Frequency
$0.7900 2014-12-17 2015-02-10 2015-02-12 2015-03-06 Yes Regular Quarter
$0.6100 2014-10-17 2014-11-10 2014-11-13 2014-12-05 Yes Regular Quarter
$0.6100 2014-07-25 2014-08-12 2014-08-14 2014-09-05 Yes Regular Quarter
$0.6100 2014-03-05 2014-05-13 2014-05-15 2014-06-06 Yes Regular Quarter
$0.6100 2013-12-13 2014-02-11 2014-02-13 2014-03-07 Yes Regular Quarter
$0.4700 2013-10-16 2013-11-12 2013-11-14 2013-12-06 Yes Regular Quarter
$0.4700 2013-07-26 2013-08-14 2013-08-16 2013-09-06 Yes Regular Quarter
$0.4700 2013-03-06 2013-05-14 2013-05-16 2013-06-07 Yes Regular Quarter
$0.4700 2012-12-13 2013-02-11 2013-02-13 2013-03-07 Yes Regular Quarter
$0.3600 2012-10-11 2012-11-13 2012-11-15 2012-12-07 Yes Regular Quarter
$0.3600 2012-07-19 2012-08-14 2012-08-16 2012-09-07 Yes Regular Quarter
$0.3600 2012-03-15 2012-05-14 2012-05-16 2012-06-07 Yes Regular Quarter
$0.3600 2011-12-15 2012-02-13 2012-02-15 2012-03-07 Yes Regular Quarter
$0.2800 2011-10-13 2011-11-15 2011-11-17 2011-12-08 Yes Regular Quarter
$0.2800 2011-07-28 2011-08-16 2011-08-18 2011-09-08 Yes Regular Quarter
2-for-1 1999-10-20 1999-11-22 1999-11-05 1999-11-19 NM Stock Split NM
2-for-1 1999-01-28 1999-03-01 1999-02-12 1999-02-26 NM Stock Split NM
$0.0002 1997-02-19 1997-03-24 1997-03-21 1997-03-21 Unknown Unknown unknown
2-for-1 1995-07-20 1995-08-16 1995-08-01 1995-08-15 NM Stock Split NM
Company Profile

AMGN Company Profile

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology

Amgen (AMGN) - this company discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. The company markets recombinant protein therapeutics in supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN erythropoietic-stimulating agents that stimulate the production of red blood cells; Neulasta and NEUPOGEN to stimulate the production of neutrophils, which is a type of white blood cell that helps the body to fight infections; and Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body's response to inflammatory diseases. The company also markets other products comprising Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, it provides Denosumab, a human monoclonal antibody that targets RANKL, an essential regulator of osteoclasts. Further, the company offers product candidates in mid-to-late stage development in a variety of therapeutic areas, including oncology, hematology, inflammation, bone, nephrology, cardiovascular, and general medicine consisting of neurology. It markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and wholesale distributors of pharmaceutical products. The company has various collaborative arrangements with Pfizer Inc.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Daiichi Sankyo Company, Limited; Array BioPharma Inc.; Kyowa Hakko Kirin Co. Ltd.; and Cytokinetics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

High Yield Stocks

High Yield Stocks

Looking for dividend stocks with great yields? Visit our list of:

High Yield Dividend Stocks
News

Amgen News